Cost of illness of advanced ovarian carcinoma in Italy: results of an empirical, single-centre study

Carlo Lazzaro, Francesco Plotti, Stella Capriglione, Matteo Ferrario, Roberto Angioli

DOI: https://doi.org/10.7175/fe.v16i3.1181

Abstract

AIM: To perform an empirical, single-centre, retrospective and secondary cost of illness (COI) study of advanced ovarian carcinoma (AOC) in Italy. METHODS: Demographic, clinical, health care and non-health care resource consumption data concerning a convenience sample of subsequent patients in 1st line of treatment (100 patients), 2nd line of treatment A (surgery + chemotherapy; 30 patients) and 2nd line of treatment B (chemotherapy only; 20 patients) were obtained from a database created in 2011 by the Obstetrics and Ginecology Unit at Campus Biomedico teaching hospital, Rome. Patients were followed-up for 2 years. Resources were valued according to the above mentioned database and literature, following the societal viewpoint. Costs are expressed in Euro (€) 2014 and reported as mean and standard deviation (SD). RESULTS: One-year COI for 1st line of treatment reaches € 44,999.7 (SD: €28,757.3), € 55,410.8 (SD: € 32,454.6) and €46,895.6 (SD: € 28,407.4) for 2nd line of treatment A and B, respectively. Regardless the line of treatment, COI is mainly driven by cost borne by patient and her family. Due to the high costs of relapse the mean COI per patient after 2 years from the diagnosis of AOC equals € 81,869.4 (SD: € 30,660.9), or 182% of the COI for the 1st line of treatment. CONCLUSIONS: Despite some limitations, our results show that increasing progression-free survival could well reduce the COI for AOC in Italy.

Keywords

Oncology; Gynecology; Advanced ovarian carcinoma

Full Text:

HTML PDF

References

  • AIOM – Associazione Italiana Oncologia Medica, AIRTUM - Associazione Italiana Registri Tumori. I numeri del cancro in Italia 2014. Brescia: Intermedia editore, 2012
  • Linee guida AIOM – Associazione Italiana Oncologia Medica. Tumori dell’ovaio, 2014. Available at: http://www.aiom.it/area+pubblica/area+medica/prodotti+scientifici/linee+guida/1%2C333%2C1%2C (last accessed 16 April 2014)
  • FIGO (Fédération Internationale de Gynécologie et d’Obstétrique). Classification FIGO (Féderation Internationale de Gynécologie Obstétrique). Classification FIGO des carcinomes du col utérin. Available at: http://screening.iarc.fr/viaviliappendix1.php?lang=2 (last accessed 20 June 2014)
  • Hong DG, Park NY, Chong GO, et al. Laparoscopic second look operation for ovarian cancer: single center experiences. Minim Invasive Ther Allied Technol 2011; 20: 346-51; http://dx.doi.org/10.3109/13645706.2011.556648
  • Mercado C, Zingmond D, Karlan BY, et al. Quality of care in advanced ovarian cancer: the importance of provider specialty. Gynecol Oncol 2010; 117: 18-22; http://dx.doi.org/10.1016/j.ygyno.2009.12.033
  • Harter P, Sehouli J, Reuss A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J of Gynecol Cancer 2011; 21: 289-95; http://dx.doi.org/10.1097/IGC.0b013e31820aaafd
  • Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer Gynecologic Oncology Group. N Engl J Med 2011; 365: 2473-83; http://dx.doi.org/10.1056/NEJMoa1104390
  • Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-96; http://dx.doi.org/10.1056/NEJMoa1103799
  • Lorusso D, Mancini M, Di Rocco R, et al. The role of secondary surgery in recurrent ovarian cancer. Int J Surg Oncol 2012; 2012: 613980; http://dx.doi.org/10.1155/2012/613980
  • Hodgson TA, Meiners MR. Cost-of illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982; 60: 429-62; http://dx.doi.org/10.2307/3349801
  • Drummond MF, Schulper MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford, UK: Oxford University Press, 2005
  • Torrance GW, Siegel JE, Luce BR. Framing and designing the cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, Weinstein MC (eds). Cost-effectiveness in health and medicine. New York, NY: Oxford University Press, 1996
  • Lohr SL. Sampling: design and analysis. 2nd ed. Boston, MA: Brooks/Cole, 2010
  • Weinstein MC, Fineberg HV. L’analisi della decisione in medicina clinica. Milan: Franco Angeli Editore, 1994
  • Briggs A, Schulper M, Claxton K. Decision modelling for health economic evaluation. Oxford, UK: Oxford University Press, 2006
  • Istituto Nazionale per la Previdenza Sociale. Permessi retribuiti legge 104. Available at: http://www.inps.it/portale/default.aspx?itemdir=5941 (last accessed 16 April 2014)
  • Contabilità economica per centri di costo del Policlinico Universitario Campus Biomedico di Roma. Anno 2011. Dati non pubblici forniti dal Policlinico Universitario Campus Biomedico di Roma
  • Ministero della Salute. Decreto 18 ottobre 2012. Remunerazione prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. (13A00528) Supplemento Straordinario n. 2 alla Gazzetta Ufficiale n. 23, 28 January 2013, Serie generale
  • Casati G. Il sistema di prezzi di trasferimento. In: Casati G (ed). Manuale di contabilità direzionale nelle aziende sanitarie. Milano: EGEA, 1996
  • Turolla A. La determinazione e il controllo dei costi nelle organizzazioni ospedaliere. Milano: Giuffrè, 1997
  • Regione del Veneto. Coordinamento regionale sul farmaco. UVEF (Unità di valutazione dell’efficacia del farmaco) Verona. Report di valutazione relativo al “biomarcatore del tumore ovarico HE4”. Verona, 8 febbraio 2011. Available at: http://www.cruf.veneto.it/ (last accessed 30 December 2014).
  • Torrino Management s.a.s. Ricerca Farmaci. Available at: http://www.torrinomedica.it/farmaci/ricercadbfarmaci/RisultatiIndiceFarmaciAuto.asp (last accessed 28 April 2014)
  • Farmaprice. Sacche a fondo chiuso colostomia. Available at: http://www.farmaprice.it/sacche-colostomia-sacche-fondo-chiuso-colostomia-colodre (last accessed 23 April 2014)
  • Bussola sanità. Ticket sanitari: l’elenco completo dei prezzi. Available at: http://www.bussolasanita.it/ (last accessed 21 April 2014).
  • Posnet J, Ian S. Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ 1996; 5: 13-23; http://dx.doi.org/10.1002/(SICI)1099-1050(199601)5:1<13::AID-HEC182>3.0.CO;2-J
  • Federproprietà, Uppi, Confappi, Fesica Confsal, Confsal Fisals. Contratto collettivo nazionale di lavoro colf e badanti 2008. Rome: 12 June 2008
  • Agenzia delle Entrate. Annuario del contribuente 2013. Parte III:2. Available at: http://www.agenziaentrate.gov.it/ (last accessed 16 April 2014).
  • Istituto Nazionale per la Previdenza Sociale. Canale informazioni. Available at: http://www.inps.it/portale/default.aspx?sID=%3b0%3b5637%3b6537%3b&lastMenu=6537&iMenu=1&iNodo=6537&p4=2 (last accessed 30 December 2014)
  • Banca d’Italia. I bilanci delle famiglie italiane nell’anno 2012. Supplementi al Bollettino Statistico. Nuova serie. Anno XXIV – Numero 5. Rome: Banca d’Italia, 27 January 2014: 63
  • Sculpher M. The role and estimation of productivity costs in economic evaluations. In: Drummond M, McGuire A (eds). Economic evaluation in health care: merging theory with practice. Oxford, UK: Oxford University Press, 2001
  • Sistema Statistico Nazionale - Istituto Nazionale di Statistica. Prezzi al consumo. Available at: http://www.istat.it/it/archivio/98601 (last accessed 14 April 2014)
  • Fattore G per Gruppo di lavoro Associazione Italiana di Economia Sanitaria (AIES). Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. Pharmacoeconomics – Italian Research Articles 2009; 11: 83-93
  • Pagano M, Gauvreau K. Fondamenti di biostatistica. 2a ed. Naples: Idelson-Gnocchi, 2003
  • Brouwer W, Rutten F, Koopmanschap M. Costing in economic evaluations. In: Drummond M, McGuire A (eds). Economic evaluation in health care: merging theory with practice. Oxford, UK: Oxford University Press, 2001
  • Havrilesky LJ, Broadwater G, Davis DM, et al. Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol Oncol 2009; 113: 216-20; http://dx.doi.org/10.1016/j.ygyno.2008.12.026
  • EuroQol Group. EQ-5D-5L Value Sets. Available at: http://www.euroqol.org/about-eq-5d/valuation-of-eq-5d/eq-5d-5l-valuesets.html (last accessed 30 April 2015)
  • Yabroff KR, Kim Y. Time costs associated with informal caregiving for cancer survivors. Cancer 2009; 115 (18 Suppl): 4362-73; http://dx.doi.org/10.1002/cncr.24588
  • Giorgi Rossi P, Beccaro M, Miccinesi G, et al. Dying of cancer in Italy: impact on family and caregiver. The Italian Survey of Dying of Cancer. J Epidemiol Community Health 2007; 61: 547-54; http://dx.doi.org/10.1136/jech.2005.045138
  • Burger RA, Brady MF, Rhee J, et al. Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol 2013; 131: 21-6; http://dx.doi.org/10.1016/j.ygyno.2013.07.100
  • Chan JK, Herzog TJ, Hu L, et al. Bevacizumab in treatment of high-risk ovarian cancer-a cost-effectiveness analysis. Oncologist 2014; 19: 523-7; http://dx.doi.org/10.1634/theoncologist.2013-0322
  • Mehta DA, Hay JW. Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer. Gynecol Oncol 2014; 132: 677-83; http://dx.doi.org/10.1016/j.ygyno.2014.01.021

Refbacks

  • There are currently no refbacks.




© SEEd srl